Drugs in development for relapsing multiple sclerosis (Q38101004)

28 August 2017

Drugs in development for relapsing multiple sclerosis (English)

1 reference

28 August 2017

0 references

3

1 reference

28 August 2017

Rehiana Ali

1

1 reference

PubMed ID

23609782

28 August 2017

Richard St John Nicholas

series ordinal

2

1 reference

28 August 2017

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

7

1 reference

28 August 2017

625-650

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0030-6

28 August 2017

0 references

cites work

Paul Ehrlich's magic bullets

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Recent insights into the mechanism of action of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mitoxantrone: benefits and risks in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mitoxantrone and cytotoxic drugs' mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Safety profile of Tysabri: international risk management plan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Fingolimod is a potential novel therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Getting specific: monoclonal antibodies in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Monoclonal antibodies in MS: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Drug insight: using monoclonal antibodies to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Monoclonal antibodies in the therapy of multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rediscovering alemtuzumab: current and emerging therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab and multiple sclerosis: therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Melanoma following treatment with alemtuzumab for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rituximab and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rituximab: beyond simple B cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Ocrelizumab: a step forward in the evolution of B-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

CNS vasculitis in a patient with MS on daclizumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Pharmacokinetics of oral fumarates in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Oral laquinimod treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Estrogen treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

Proteinuria with fumaric acid ester treatment for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0030-6

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

12 December 2020

Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment

1 reference

12 December 2020

A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis

1 reference

12 December 2020

Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes

1 reference

12 December 2020

Insight into the mechanism of laquinimod action

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

12 December 2020

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

1 reference

12 December 2020

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

Spotlight on fumarates.

1 reference

12 December 2020

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

1 reference

12 December 2020

Spotlight on alemtuzumab.

1 reference

12 December 2020

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Mitoxantrone treatment of multiple sclerosis: safety considerations

1 reference

12 December 2020

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

12 December 2020

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?

1 reference

12 December 2020

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

12 December 2020

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

1 reference

12 December 2020

A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

1 reference

12 December 2020

Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells

1 reference

12 December 2020

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

1 reference

12 December 2020

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

12 December 2020

Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child

1 reference

12 December 2020

Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms

1 reference

12 December 2020

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

12 December 2020

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data

1 reference

12 December 2020

10.1007/S40265-013-0030-6

Identifiers

DOI

1 reference

PubMed ID

23609782

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23609782